The tumor protein p53 (TP53) arginine-to-histidine mutation at codon 337 (R337H) predisposes children to adrenocortical tumors (ACTs) and, rarely, to other childhood tumors, but its impact on adult cancer remains undetermined. The objective of this study was to investigate the frequency and types of cancer in relatives of children with ACT who carry the TP53 R337H mutation. METHODS: TP53 R337H testing was offered to relatives of probands with ACT. The parental lineage segregating the R337H mutation was identified in all families. The frequency and distribution of cancer types were compared according to R337H status. The authors' data also were compared with those publicly available for children with TP53 mutations other than R337H. RESULTS: The mean and median follow-up times for the probands with ACT were 11.2 years and 9.7 years (range, 3-32 years), respectively. During this time, cancer was diagnosed in 12 of 81 first-degree relatives (14.8%) carrying the R337H mutation but in only 1 of 94 noncarriers (1.1%; P 5.0022). At age 45 years, the cumulative risk of cancer was 21% (95% confidence interval, 5%-33%) in carriers and 2% (95% confidence interval, 0%-4%) in noncarriers (P 5.008). The frequency of cancer was higher in the R337H segregating lineages than in the nonsegregating lineages (249 of 1410 vs 66 of 984 individuals; P <.001). Breast and gastric cancer were the most common types. CONCLUSIONS: TP53 R337H carriers have a lifelong predisposition to cancer with a bimodal age distribution: 1 peak, represented by ACT, occurs in the first decade of life, and another peak of diverse cancer types occurs in the fifth decade. The current findings have implications for genetic counseling and surveillance of R337H carriers.
INTRODUCTION
Individuals who carry germline tumor protein 53 (TP53) mutations have an increased risk of developing cancer. 1 The association of TP53 mutations with familial cancer predisposition was discovered in the early 1990s from studies of families that fulfilled the classic clinical criteria for Li-Fraumeni syndrome (LFS) (Online Mendelian Inheritance in Man no. 151623). 2, 3 In this syndrome, there is an autosomal dominant cancer distribution pattern that includes soft tissue and bone sarcomas and breast, brain, leukemia, and adrenocortical tumors (ACTs). 1, 3 Approximately 80% of individuals with cancer in classic LFS families carry pathogenic germline TP53 mutations that typically alter the p53 DNA-binding domains. 4, 5 The cancer penetrance and profile has not been defined in carriers of TP53 mutations outside the p53 DNA-binding domains. 5 These germline mutations, which were first revealed in children with ACT, have been designated low-penetrance mutants. [6] [7] [8] The TP53 R337H mutation, which is associated with the cluster of pediatric ACTs and other tumors 6, 9, 10 in southern Brazil, is 1 example of this class of lowpenetrance mutants. There has been controversy about the genotype-phenotype correlations for patients with the R337H mutation. 11 Some reports have described families with typical LFS phenotypes, whereas others have described families with a paucity or no history of cancer. 7, 8, 12 This uncertainty about the clinical implications of the R337H mutation in presymptomatic individuals has been a barrier to genetic counseling and surveillance. The objective of the current study was to compare the frequency, age at diagnosis, and type of cancer in relatives of children with ACT who were in the TP53 R337H segregating lineage with the corresponding data for relatives in the nonsegregating lineage. We also compared our data with those for relatives of children with ACT or sarcoma with pathogenic TP53 mutations who were reported to the International Agency for Research on Cancer (IARC) database.
MATERIALS AND METHODS

Patients and First-Degree Relatives
From December 1980 to December 2014, 137 patients aged < 21 years were diagnosed with ACT at the Boldrini Children's Center, Campinas, Brazil. Between December 2002 and December 2014, 55 families enrolled on this study were followed for at least 3 years after the diagnosis. The pathologic diagnosis of ACT, histologic classification, disease staging, and TP53 R337H identification were performed as previously described. 7, 13, 14 Cancer diagnoses in first-degree relatives were verified from pathology reports or death certificates. For other relatives, cancer was ascertained from pathology reports, death certificates, or verbal reporting. The study was approved by the Boldrini Children's Center Institutional Review Board (IRB) and by the IRBs of the School of Medical Sciences-University of Campinas (UNICAMP) and St Jude Children's Research Hospital. Informed consent was obtained from each participant or their guardians.
Family Cancer History
The demographic and clinical characteristics of the patients were obtained from medical records. The history of cancer was obtained annually and prospectively from patients, parents, and relatives by 1 of the investigators (M.J.M.). The 55 enrolled patients with newly diagnosed ACT were considered the probands. Relatives from 5 different generations were classified according to their biologic relationship with the probands in the first, second, or third degree.
All first-degree relatives were invited to be genotyped and were classified as carriers or noncarriers of the TP53 R337H mutation. Second-degree and third-degree relatives were classified according to their R337H mutation status in R337H segregating and nonsegregating parental lineages. The occurrence of cancer in relatives of the probands was recorded and compared with respect to their R337H status.
The pedigrees were drawn up by using Cyrillic version 2.1 software (Cherwell Scientific, London, UK). The genetic data were managed using Multipoint Engine for Rapid Likelihood Inference (MERLIN) software.
IARC Data
The IARC TP53 database, version R17, was used to obtain the family history of cancer for probands younger than 16 years who had ACT or sarcoma and who carried germline TP53 non-R337H mutations (http://p53.iarc. fr/DownloadDataset.aspx. Accessed April 21, 2016).
Statistical Analysis
The quasi-likelihood score (WQLS) 15 method, implemented in the GDT software (version 0.1.1), was used to test for associations between cancer and the TP53 R337H mutation. 15 The cumulative incidence of cancer in firstdegree relatives of probands carrying the R337H mutation and in relatives who tested negative for the R337H mutation was estimated in a marginal Cox proportionalhazards model with a robust sandwich estimate by considering the family variable as a clustering variable 16 and was tested by using the frailty model 17 to account for withincluster correlation. Time to event was defined as the time from birth until the development of cancer, censoring those still alive. The Fisher exact test was applied by means of contingency tables to compare the cancer frequency in R337H-affected parental lineages with that in lineages with non-R337H mutations of TP53 (from the IARC TP53 database), without any adjustment. The associations were considered statistically significant when the P values were < .05. SPSS version 21.0 (IBM Corporation,months). All probands were white and carried the TP53 R337H mutation. Other patient characteristics are provided in Supporting Table 1 (see online supporting information).
Age of Onset and Cancer Types in First-Degree Relatives Tested for the R337H Mutation TP53 R337H status was determined in 175 of 179 firstdegree relatives of the probands. Thirty-three mothers, 22 fathers, 22 of 62 siblings, and 4 of 7 offspring of probands carried the R337H mutation. Six of the 55 carrier parents were not tested directly but were obligate carriers. Therefore, the lineage segregating the R337H mutation was established in all 55 families.
The mean and median follow-up times for the probands with ACT were 11.2 years and 9.7 years, respectively (range, 3-32 years). During this time, cancer was diagnosed in 12 of 81 (14.8%) first-degree relatives of probands who carried the R337H mutation but in only 1 of 94 (1.1%) first-degree relatives who were genotyped as negative for the mutation (Fig. 1A) .
Individuals with the R337H mutation were 5.7 times more likely to have cancer than those lacking the mutation (WQLS test, P 5 .0022). The median ages of the fathers and mothers at the diagnosis of their cancers were 46 years (range, 28-62 years) and 44 years (range, 41-61 years), respectively. The only cancer reported among the 94 R337H noncarrier first-degree relatives was acute myeloid leukemia in a woman aged 23 years.
Of 12 first-degree carrier relatives who developed cancer, 8 died and 4 remain alive, although 2 of the latter individuals have progressive disease. One mother is alive without evidence of disease 6 years after being diagnosed with breast cancer. One proband sibling, a girl aged 1.3 years, developed ACT and was alive with no evidence of disease 5.7 years after diagnosis (Table 1) .
With 1 exception, all cancers in parents occurred in individuals older than 40 years. At age 45 years, the cumulative risk of cancer was 21% (95% confidence interval, 5%-33%) in R337H-carrying first-degree relatives compared with 2% (95% confidence interval, 0%-4%) in noncarriers (P 5 .008) (Fig. 1B) .
Comparison of Frequency and Cancer Types According to the R337H Segregating Status of the Parental Lineages
Of the 110 parental lineages, there was a known history of cancer in 50 of the 55 R337H segregating lineages and in 49 of the 55 R337H nonsegregating lineages. Cancer was recorded in 249 of 1410 individuals (17.6%), including probands, in the R337H segregating lineages and in 66 of 984 individuals (6.7%) in the nonsegregating lineages ( Fig. 2A) . The frequency of cancer in the R337H segregating lineages was significantly higher than that in the nonsegregating lineages (249 vs 66; WQLS test, P 5 4.6 3 10 -22 ) ( Fig. 2A) . When only proband ancestors were considered in the analysis, the number of cancer cases remained significantly higher in the R337H segregating lineages than in the nonsegregating lineages (181 vs 65; WQLS test, P 5 2.3 3 10
28
). Proband ancestors in the R337H segregating lineages were 1.58 times more likely to develop cancer than individuals in the nonsegregating lineages.
The comparative frequency of different cancer types with respect to R337H segregating status is provided in Table 2 . The frequency of gastric, adrenocortical (excluding probands with ACT), and hematopoietic neoplasms was significantly higher among individuals in the R337H segregating lineages than among those in the nonsegregating lineages. Remarkably, gastric cancer was the most common cancer type overall. In women, gastric cancer was the second most common cancer in the R337H segregating lineages, and the incidence was significantly higher than in the nonsegregating lineages (16.8% vs 6%; P < .0001). Breast and intestine cancers also occurred frequently in the R337H segregating lineages, but their frequency was not significantly different from that in the nonsegregating lineages.
The age at diagnosis of cancer was known for 161 of 194 relatives (83%) in the R337H segregating lineages and for 47 of 66 relatives (71.2%) in the nonsegregating lineages. In both sets of parental lineages, most cancers occurred in individuals aged >50 years, although there were more cancer cases in relatives aged >45 years in the R337H segregating lineages (P 5 .03) (Supporting Table  2 ; see online supporting information). The pattern of cancer distribution among relatives of probands was compared in the R337H segregating and nonsegregating lineages. In addition to the probands' ACTs, some type of cancer was recorded in 47 of 50 families (94%) in the R337H segregating lineages and in 27 of 49 families (55.1%) in the nonsegregating lineages (P < .001); the co-occurrence of cancer in family members with different degrees of proximity to the proband was observed in 25 of 47 families (53.2%) in the R337H segregating lineages and in only 4 of 27 families (14.8%) in the contralateral lineages (P 5 .001). Conversely, isolated cases of cancer in second-degree or third-degree relatives were significantly associated with the R337H nonsegregating lineages (23 of 27 [85.2%] vs 22 of 47 [46.8%]; P 5 .001) ( Table 3) .
Second cancers occurred infrequently in R337H carriers. Among the probands with ACT, 2 had synchronous cancers, and 2 had metachronous cancers. Among the Abbreviations: R337H, arginine-to-histidine R337H, arginine-to-histidine mutation at codon 337; TP53, tumor protein p53.
Original Article proband relatives in the R337H segregating lineages, 4 developed multiple malignant neoplasms (Supporting Table 3 ; see online supporting information). We compared the family history of cancer among probands in the IARC database who had ACT or sarcoma with pathogenic germline TP53 mutations (R337H excluded) with that of our cohort. The distribution of cancer types among individuals in the R337H segregating lineages was strikingly different from that among individuals in the IARC database (Table 4 ).
History of Cancer in Relatives of
The proportion of gastric cancers in relation to all tumors was significantly higher among individuals in the R337H segregating lineages than among those in the non-R337H segregating lineages of probands with ACT (18.7% vs 2%; P < .0001) or sarcomas (18.7% vs 4.7%; P < .0001). Conversely, the proportion of brain cancers and soft tissue and bone sarcomas was significantly higher among individuals in the non-R337H segregating lineages of probands with ACT (P 5 .01, P 5 .007, and P 5 .001, respectively) or sarcomas (P 5 .0004, P < .0001, and P 5 .001, respectively) than among those in the R337H segregating lineages. Remarkably, the proportion of breast cancer was twice as high among individuals in the non-R337H segregating lineages of probands with sarcomas than among those in the R337H segregating lineages (52.5% vs 24.2%; P < .0001) ( Table 4) . Finally, we compared the frequency of multiple cancers in probands who had ACT and their relatives in the R337H segregating lineages with that in probands and their relatives who had ACT or sarcoma segregating TP53 mutations other than R337H (Table 4) . Probands in the IARC database had significantly more multiple cancers compared with the study cohort (P < .0001) ( Table 4 ). The frequency of multiple cancers in relatives of probands with sarcoma in the IARC database was also significantly higher than that in relatives in the R337H segregating lineages (P < .0001) ( Table 4) .
DISCUSSION
The main finding of the current study is that, among relatives of children with ACT, individuals in the TP53 R337H segregating lineages had a significantly higher incidence of cancer than relatives in the contralateral lineages. The risk of developing cancer was approximately 50% higher among individuals in the R337H segregating lineages than among those in the R337H nonsegregating lineages. Excluding the probands, the excess of cancer remained significantly associated with R337H segregating status. This association with the R337H mutation was noted in all age groups.
The age at diagnosis of cancer for individuals in the R337H segregating lineages differed from that for individuals in classic LFS families. In the R337H segregating lineages, excluding the probands with ACT, 27.3% of cancers occurred in individuals aged <45 years. Conversely, in families reported to the IARC in which a proband with ACT carried a TP53 mutation other than R337H, approximately 76.4% of cancers developed in individuals aged <45 years. Similarly, a recent report from the American LFS cohort noted that, among 286 individuals who had a germline TP53 mutation of any kind, the cumulative cancer incidence was 50% by ages 31 years and 46 years for women and men, respectively. 18, 19 Moreover, the French LFS Working Group observed that 22 of 37 breast cancers (60%) occurred in women aged <36 years. 20 Conversely, in the R337H segregating lineages, all 20 breast cancers were diagnosed in patients aged >40 years (median age, 50 years; range, 41-72 years).
The development of multiple cancers in TP53 carriers is another hallmark of classic LFS families. More than 40% of these individuals develop second tumors, usually within 10 years after diagnosis of the primary tumor. 20, 21 In our cohort, with follow-up extended to July 2016, of 85 R337H carriers who developed cancer, 4 (4.7%) developed secondary cancers.
The distribution of cancer types among R337H segregating lineages differs from that among LFS families in the IARC database or that reported in the literature. 22 In the IARC families, relatives of probands with ACT or sarcomas had significantly more breast, brain, soft tissue, and bone tumors than relatives of probands with ACT in R337H segregating lineages. Conversely, gastric, intestinal, and larynx cancers were significantly more common among individuals in the R337H segregating lineages than among individuals in the IARC non-R337H segregating lineages. The distribution of cancer types also was different in children. In the IARC families with a proband who had ACT, greater than 80% of the other pediatric cancers were brain, soft tissue, or bone tumors. In our study cohort, excluding the probands, ATCs and brain tumors accounted for 73% of all pediatric cancers.
The frequency and pattern of cancer among families with inherited TP53 mutations may depend on the p53 mutant properties. Different types of p53 mutants have distinct characteristics related to their tridimensional structure (conformational mutants) or contact with DNA regions (DNA contact-defective mutants). 5 Furthermore, some p53-mutant proteins (gain-of-function mutants) have acquired oncogenic properties that contribute to cell proliferation, invasion, and angiogenesis. 23 It appears that, in families with a proband who had sarcoma and a high frequency of LFS core-component cancers, gain-offunction p53 mutants predominate (Supporting Fig. 1 ; see online supporting information). 23 Conversely, the R337H mutant is a prototype of a conformational mutant, which retains transactivation activity, and is associated with a selective pattern of tissue-associated and ageassociated cancers. 24 The contribution of the R337H mutation to the incidence of individual cancer types and the implications for the overall cancer burden in the general southern Brazilian population are unknown. In our study families, breast, brain, and soft tissue cancers were not overrepresented among those cancers affecting young adults in the R337H segregating lineages. These data are consistent with other studies from Brazil demonstrating that the frequency of the R337H mutation among women with breast cancer varies from 3% to 9%, depending on the patient selection criteria. 12, 25 Gastric cancer appears to be overrepresented for both men and women in the R337H segregating lineages compared with the general population (Supporting Table  4 ; see online supporting information). Moreover, in the affected lineages of 62 LFS families with any TP53 mutation, gastric or gastroesophageal junction cancers were Original Article diagnosed in only 21 of 429 individuals (4.9%; median age, 36 years). 26 Conversely, gastric cancers accounted for 18.7% of all cancers, and this was the most common cancer type among men in our series. These observations suggest that the incidence of gastric cancer might be substantially higher than the baseline rate among older adults in the R337H segregating lineages in the southern Brazilian population. In our previous study, we observed that the stability of the tetramers formed by the p53 R337H is altered by the pH. 27 It is intriguing that gastrointestinal cancers appear to be more frequent in the R337H nonsegregating lineages than in the general population. Taken together, our findings suggest that environmental, infectious, or other genetic factors to be determined collaborate with p53 R337H to increase the incidence of gastrointestinal cancers in R337H families.
The estimated median incidence of the TP53 R337H mutation is approximately 1 in 350 newborns in the southern Brazilian population. 28, 29 This contrasts with the rate of 1 in 5000 for any type of TP53 mutation in the general population outside this geographic region. 30 There is no evidence that R337H affects reproductive fitness; most carriers do not develop cancer until late in life and thus are healthy in their reproductive years. Considering that the R337H allelic frequency remains stable, the number of R337H-associated cancers is expected to increase, because the life expectancy of the population in this region of Brazil has increased from 54.7 years in 1960 to 74.4 years in 2014, and this age interval corresponds to that in which most cancers associated with the R337H mutation are expected to occur.
There has been controversy regarding whether detection of the R337H mutation should be included in the universal newborn screening program in this Brazilian region and whether relatives of children carrying the R337H mutation should be tested for it. A surveillance program designed to facilitate early diagnosis and treatment of children at high risk for ACT was associated with an improved outcome. 28 The importance of early diagnosis in pediatric ACT has been further supported by genomic findings, which demonstrated a dramatic increase in deleterious acquired genetic alterations with increasing ACT weight and stage. 24 Early detection has also been associated with increased survival of individuals in LFS families. 31 Gastrointestinal and breast cancers were common among aging individuals in lineages segregating the R337H mutation and are amenable to prevention and early detection. Finally, certain lifestyle patterns have been associated with an increased risk of cancer 32 ; hence, educating R337H carriers may modify the cancer risk in this population.
In summary, our study revealed that, in families that have a child with ACT, individuals in the TP53 R337H segregating lineage have an increased risk of developing cancer compared with relatives in the contralateral lineage. Members of R337H families who develop cancer are typically older at diagnosis than their counterparts in classic LFS families, and R337H and LFS families also differ in the types of cancer that predominate. In R337H carriers, the risk of developing cancer is highest in the fifth decade of life, resulting in an increased R337H-associated cancer burden among older adults. Finally, in view of our findings, screening for R337H of all children and adults at risk of inheriting the R337H mutation should be considered, and age-adapted and sex-adapted cancer surveillance should be offered to all children and adults who carry this mutation.
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